乳腺癌 Nectin-4 靶向治疗策略：最新进展与未来展望。

IF 5.7 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Breast Pub Date : 2024-11-14 DOI:10.1016/j.breast.2024.103838

Yufei Wang , Guangliang Li , Hanying Wang , Quan Qi , Xian Wang , Haiqi Lu

{"title":"乳腺癌 Nectin-4 靶向治疗策略：最新进展与未来展望。","authors":"Yufei Wang , Guangliang Li , Hanying Wang , Quan Qi , Xian Wang , Haiqi Lu","doi":"10.1016/j.breast.2024.103838","DOIUrl":null,"url":null,"abstract":"<div><div>Nectin-4 is a cell adhesion molecule which has gained more and more attention as a therapeutic target in cancer recently. Overexpression of Nectin-4 has been observed in various tumors, including breast cancer, and is associated with tumor progression. Enfortumab vedotin(EV)is an antibody-drug conjugate (ADC) targeting Nectin-4, which has been approved by FDA for the treatment of urothelial carcinoma. Notably, Nectin-4 was also investigated as a target for breast cancer in preclinical and clinical settings. Nectin-4-targeted approaches, such as ADCs, oncolytic viruses, photothermal therapy and immunotherapy, have shown promising results in early-phase clinical trials. These therapies offer novel strategies for delivering targeted treatments to Nectin-4-expressing cancer cells, enhancing treatment efficacy and minimizing off-target effects. In conclusion, this review aims to provide an overview of the latest advances in understanding the role of Nectin-4 in breast cancer and discuss the future development prospects of Nectin-4 targeted agents.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103838"},"PeriodicalIF":5.7000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects\",\"authors\":\"Yufei Wang , Guangliang Li , Hanying Wang , Quan Qi , Xian Wang , Haiqi Lu\",\"doi\":\"10.1016/j.breast.2024.103838\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Nectin-4 is a cell adhesion molecule which has gained more and more attention as a therapeutic target in cancer recently. Overexpression of Nectin-4 has been observed in various tumors, including breast cancer, and is associated with tumor progression. Enfortumab vedotin(EV)is an antibody-drug conjugate (ADC) targeting Nectin-4, which has been approved by FDA for the treatment of urothelial carcinoma. Notably, Nectin-4 was also investigated as a target for breast cancer in preclinical and clinical settings. Nectin-4-targeted approaches, such as ADCs, oncolytic viruses, photothermal therapy and immunotherapy, have shown promising results in early-phase clinical trials. These therapies offer novel strategies for delivering targeted treatments to Nectin-4-expressing cancer cells, enhancing treatment efficacy and minimizing off-target effects. In conclusion, this review aims to provide an overview of the latest advances in understanding the role of Nectin-4 in breast cancer and discuss the future development prospects of Nectin-4 targeted agents.</div></div>\",\"PeriodicalId\":9093,\"journal\":{\"name\":\"Breast\",\"volume\":\"79 \",\"pages\":\"Article 103838\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Breast\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0960977624001693\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960977624001693","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

Nectin-4 是一种细胞粘附分子，近年来作为癌症治疗靶点受到越来越多的关注。在包括乳腺癌在内的多种肿瘤中都观察到了 Nectin-4 的过表达，并且与肿瘤的进展有关。Enfortumab vedotin（EV）是一种以Nectin-4为靶点的抗体药物共轭物（ADC），已被FDA批准用于治疗尿路上皮癌。值得注意的是，在临床前和临床中，Nectin-4 也被作为乳腺癌的靶点进行了研究。以 Nectin-4 为靶点的方法，如 ADCs、溶瘤病毒、光热疗法和免疫疗法，已在早期临床试验中显示出良好的效果。这些疗法为向表达 Nectin-4 的癌细胞提供靶向治疗、提高疗效和减少脱靶效应提供了新策略。总之，本综述旨在概述了解 Nectin-4 在乳腺癌中作用的最新进展，并探讨 Nectin-4 靶向药物的未来发展前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects

查看原文本刊更多论文

Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects

Nectin-4 is a cell adhesion molecule which has gained more and more attention as a therapeutic target in cancer recently. Overexpression of Nectin-4 has been observed in various tumors, including breast cancer, and is associated with tumor progression. Enfortumab vedotin(EV)is an antibody-drug conjugate (ADC) targeting Nectin-4, which has been approved by FDA for the treatment of urothelial carcinoma. Notably, Nectin-4 was also investigated as a target for breast cancer in preclinical and clinical settings. Nectin-4-targeted approaches, such as ADCs, oncolytic viruses, photothermal therapy and immunotherapy, have shown promising results in early-phase clinical trials. These therapies offer novel strategies for delivering targeted treatments to Nectin-4-expressing cancer cells, enhancing treatment efficacy and minimizing off-target effects. In conclusion, this review aims to provide an overview of the latest advances in understanding the role of Nectin-4 in breast cancer and discuss the future development prospects of Nectin-4 targeted agents.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Breast 医学-妇产科学

CiteScore

8.70

自引率

2.60%

发文量

165

审稿时长

59 days

期刊介绍： The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.